T1	Participants 526 600	467 women with type 1 or 2 endometrial cancer and 582 age-matched controls
T2	Participants 675 733	tumor specimens of 46 women with type 1 endometrial cancer
T3	Participants 1319 1366	patients with the variant and wild-type alleles
